Zacks.com on MSN1h
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer
The FDA's nod is based on late-stage data, which show AZN's Datroway cuts the risk of disease progression/death by 37% vs chemotherapy in certain breast cancer patients.
AstraZeneca And Daiichi Sankyo's Datroway Gets US Approval For Metastatic HR+ Breast Cancer
British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab ...
Daily11h
AstraZeneca-Daiichi Sankyo Datroway gets USFDA nod for previously treated Metastatic HR Positive, HER2 Negative Breast Cancer
Tokyo: Daichi Sankyo has announced that DATROWAY (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the ...
PMLiVE8h
AstraZeneca/Daiichi Sankyo’s Datroway granted FDA approval in breast cancer
AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) has been approved by the US Food and Drug ...
Contract Pharma6h
FDA Approves AstraZeneca & Daiichi Sankyo’s Datroway for Metastatic Breast Cancer
The approval was based on results from the TROPION-Breast01 Phase III trial.
pharmaphorum20h
Kelun's MSD-partnered TROP2 drug gets first okay in China
The approval means Kelun has brought its TROP2 ADC to market ahead of AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan (Dato-DXd), whose FDA filing in non-small cell lung cancer (NSCLC ...
Daiichi Sankyo Shares Jump After U.S. FDA Approves Breast Cancer Drug
Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39, on Monday ...